On the safety of reduced nicotinamide adenine dinucleotide (NADH)

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 23, Issue 3, 2004, Pages 179-194

  Birkmayer, Jörg G D ^a,b,c   Nadlinger, Karl F R ^a   Hallström, Seth ^a,b  

^a Birkmayer Laboratories ^*  (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Birkmayer Laboratories   (Austria)

Author keywords

Maximum tolerated dose (MTD); NADH; Orally absorbable NADH; Toxicity studies

Indexed keywords

ENADA; NICOTINAMIDE ADENINE DINUCLEOTIDE; SODIUM CHLORIDE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG FATALITY; DRUG SAFETY; FECES ANALYSIS; FEMALE; FOOD INTAKE; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; WEIGHT REDUCTION; ABSORPTION; ANIMAL; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ANIMALIA; CANIS FAMILIARIS;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INFUSIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; NAD;

EID: 4344607826     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvPathToxOncol.v23.i3.20     Document Type: Article

References (27)

1. Birkmayer JGD, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH)-a new therapeutic approach to Parkinson's disease, comparison of oral and parenteral application. Acta Neurol Scand Suppl 1993;146:32-35.
2. Birkmayer JGD, Birkmayer W. The coenzyme nicotinamide adenine dinucleotide (NADH) as a biological antidepressive agent. Experience with 205 patients. New Trends Clin Neuropharmacol 1991; 5:75-86.
3. Forsyth LM, Preuss HG, MacDowell AL, Chiazze L, Birkmayer GD, Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol 1999; 82:185-191.
4. Babson AL, Babson SR. Comparative evaluation of a partial thromboplastin reagent containing a non-settling, particulate activator. Am J Clin Pathol 1974; 62:856-860.
5. Kommissionen für Enzymdiagnostik und Standardisierung: Empfehlungen der Deutschen Gesellschaft für Klinische Chemie. Z Klin Chem Klin Biochem 1972; 10:182.
6. Szasz G. New substrates for measuring gamma-glutamyl transpeptidase activity. Z. Klin Chem Klin Biochem 1974; 12:228.
7. Eisenman G, Tubin DO, Casby JU. Glass electrode for measuring sodium ions. Science 1957; 126:831-834.
8. Schmidt FH. Die enzymatische Bestimmung von Glucose und Fructose nebeneinander. Klin Wschr 1981; 39:1244-1247.
9. Pearlman FC, Lee RTY. Detection and measurement of total bilirubin in serum, with use of surfactants as solubilizing agents. Clin Chem 1974; 20:447-453.
10. Spencer K, Price CP. Influence of reagent quality and reaction conditions on the determination of serum albumin by the bromcresol green dyebinding method. Ann Clin Biochem 1977; 14:105-115.
11. Moorehead RW, Biggs HG. 2-Amino-2-methyl-1-propanol as the alkalizing agent in an improved continuous-flow cresolphthalein complex one. Procedure for calcium in serum. Clin Chem 1974; 20:1458-1460.
12. Gutmann I, Bergmeyer, HU. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis, 2 Edition, New York, London: Verlag Chemie Weinheim and Academic Press, 1974.
13. Jaffé M. Über den Niederschlag, welcher Pikrinsäure in normalen Harn erzeugt und über eine neue Reaktion des Kreatinins. Hoppe Seylers Z Physiol Chem 1886; 10:391-400.
14. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20:470-475.
15. Birkmayer JGD, Nadlinger K. Safety of stabilized, orally adsorbable, reduced nicotamide adenine dinucleotide (NADH): a 26-week oral tablet administration of ENADA®/NADH for chronic toxicity study in rats. Drugs Exp Clin Res 2002; 28:185-192.
16. Snedecor GW, Cochran WG. Statistical methods, 7th Edition Iowa: Iowa State University Press, 1980.
17. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. Am Stat Assoc J 1955; 50:1096-1121.
18. Armitage P. Statistical methods in medical research. Oxford: Blackwell, 1972, Ch. 9.
19. Levene H. Robust test for equality of variance. In: Olkin I, editor. Contributions to Probability and Statistics. Palo Alto, California, Stanford University Press, 1960.
20. Lehmann EL. Nonparametrics: statistical methods based on ranks. New York: McGraw Hill. 1975: Ch.5.
21. Jonckheere AR. A distribution free K sample test against ordered alternatives. Biometrika 1954; 41: 133-145.
22. Mattern C. Zur Entwicklung von stabilen Arzneiformen des Coenzyms NADH für die perorale und parenterale Applikation. PhD Thesis, Berlin, Humboldt University, 1996.
23. Rex A, Hentschke M-P, Fink H. Bioavailability of reduced nicotinamide-adenine-dinucleotide (NADH) in the central nervous system of the anaesthetized rat measured by laser-induced fluorescence spectroscopy. Pharmacol Toxicol 2002; 90:220-225.
24. Birkmayer GD, Kay GG, Virre E. Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit. Wien Med Wochenschr 2002; 152:450-454.
25. Moline ML, Rebeta JR, Flye BL, Zendell SM, Broch L, Ford T, Zak R, Kay GG. Effectiveness of NADH in alleviating effects of sleep deprivation in healthy middle-aged adults. First International Conference on Mechanisms of Action of Nutraceuticals (ICMAN), Dubrovnik, 2001 (Abstract).
26. Klingenberg M. Pyridinnucleotide und biologische Oxidation. In: Bucher TH, Kroger A, editors. Zur Bedeutung der freien Nukleotide II. Moosbacher Kolloquium. Heidelberg: Springer Verlag, 1960.
27. Kraft W, Dürr UM, Dreier HK, Schutze HR, Weber A. In: Kraft W, Durr UM eds. Kompendium der Klinischen Laboratoriumsdiagnostik bei Hund Katze und Pferd. Second Edition, Hannover: M.&. Shaper Verlag, 1981.